RenovoRx, Inc. announced that the pre-clinical data published in JVIR showed a 100-fold (two orders of magnitude) increase in local tissue concentration of the therapy with TAMP compared to conventional intravenous (IV) delivery approaches. TAMP's novel approach to treatment offers the potential to increase an oncology therapy's efficacy, improve safety, and widen its therapeutic window by focusing its distribution uniformly in target tissue.